Who Optimizes SG&A Costs Better? Jazz Pharmaceuticals plc or TG Therapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Jazz Pharmaceuticals plc and TG Therapeutics, Inc. have taken different paths in this regard over the past decade.

Jazz Pharmaceuticals plc: A Steady Climb

From 2014 to 2023, Jazz Pharmaceuticals saw a consistent increase in SG&A expenses, peaking in 2021 with a 257% rise from 2014. This growth reflects their aggressive expansion and investment in marketing and administration.

TG Therapeutics, Inc.: A Different Approach

Conversely, TG Therapeutics maintained a more conservative approach, with their SG&A expenses in 2023 being only about 5% of Jazz's. Their strategy focuses on lean operations, which could be advantageous in maintaining profitability.

Conclusion

While Jazz Pharmaceuticals invests heavily in growth, TG Therapeutics opts for cost efficiency. Both strategies have their merits, but the ultimate winner will be determined by market dynamics and financial sustainability.